Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Letermovir: positive Phase 3 data
AiCuris’ anti HCMV drug Letermovir meets Primary Endpoint
AiCuris’ licensee Merck reports that Letermovir, a prophylactic treatment against HCMV in bone marrow transplant patients, meets Primary Endpoint in Pivotal Phase III Study.
AiCuris in Going Public Case Studies
A Decade of Passion for Resistance-Breaking Anti-Infectives
When AiCuris was founded 10 years ago in Wuppertal, as a spin-out from Bayer Pharma, anti-infectives and the problem of increasing bacterial and viral resistance to common treatments.
Pritelivir successful in topical Ph 1
AiCuris' Anti-HSV Drug Pritelivir achieves primary endpoint in Phase 1 study
Pritelivir ointment did not show any cumulative irritation potential. This phase 1 trial is part of a second development program for Pritelivir.